Summary & Overview
HCPCS Level II J9999: Not otherwise classified antineoplastic drugs
HCPCS Level II code J9999 designates “Not otherwise classified, antineoplastic drugs” and is applied when an administered chemotherapy agent lacks a specific HCPCS Level II product code. Nationally, use of an NOC (not otherwise classified) drug code like J9999 matters because it signals instances where new, compounded, or otherwise uncoded antineoplastic therapies are delivered in ambulatory settings and billed without precise product-level coding. This can affect clinical billing workflows, medical record detail, and payer adjudication processes.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. Readers will find concise context on how J9999 is used in oncology drug administration encounters, the typical sites of service where it appears, and related coding considerations. The publication outlines comparisons with other unclassified drug or biologic codes, clarifies common clinical scenarios tied to antineoplastic therapy coding, and identifies where input data is unavailable.
The material provides practitioners, coding professionals, and policy stakeholders with a clear operational summary: what J9999 represents, the service contexts in which it appears, and the scope of payers addressed. Where specific service-line metadata or additional input data are missing, the summary indicates that data is not available in the input.
Billing Code Overview
HCPCS Level II code J9999 denotes Not otherwise classified, antineoplastic drugs. This entry is used when an antineoplastic medication administered as part of chemotherapy / drug administration does not have a more specific HCPCS Level II code.
Typical sites of service for claims using this code are physician office (POS 11) and outpatient hospital (POS 22). This code identifies administration of an antineoplastic drug when a precise product-level code is not available from the standard HCPCS Level II listings.
Clinical & Coding Specifications
Clinical Context
A patient with a confirmed or suspected malignancy presents to the oncology infusion suite in a physician office (POS 11) or outpatient hospital setting (POS 22) for administration of an antineoplastic agent that is not described by a specific HCPCS Level II drug code. The oncology nurse verifies diagnosis, obtains consent, performs chemotherapy safety checks (drug regimen, dose, infusion line), and documents medication lot numbers and administration times. The clinician orders the unclassified antineoplastic agent, pharmacy compounds or dispenses the drug, and the infusion is administered with appropriate supportive care. Documentation includes the drug name, dose, route, total amount dispensed, amount administered, amount discarded (if any), and linkage to the patients malignancy diagnosis in the medical record. Billing uses HCPCS Level II code J9999 for the drug itself and appropriate administration and encounter codes for the visit.
Coding Specifications
-
Modifiers:
-
JW: Used to report the amount of a single-dose vial of drug that is discarded and not administered to any patient. Attach when documentation supports the discarded amount for billing and reimbursement reporting. -
59: Used to indicate a distinct procedural service. Attach when the service or procedure is separate and independent from other services provided on the same date of service, supported by documentation. -
Associated provider taxonomies and specialties:
-
207RH0003X: Hematology & Oncology Physician — specialists who diagnose and manage malignant hematologic and solid tumor diseases and prescribe/oversee antineoplastic therapy.